Autopsy report · NCT03434119

Efficacy and Safety of Soliqua Versus Lantus in Ethnically/Racially Diverse Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Agents

Cause of deathOther Automatic label, confidence 0.3, unverified. How labels are made.

“("Trial terminated (recruitment delays)")”

The sponsor’s own words in the registry.

Life of this trial

Ran for about 11 months before it stopped.
241 participants enrolled.
Results were posted on the registry 1 year after it ended.

Vital statistics

Status: Terminated
Phase: Phase 3
Sponsor: Sanofi
Sponsor type: Industry
Conditions: Type 2 Diabetes Mellitus
Interventions: Insulin glargine/Lixisenatide; Insulin glargine (HOE901); Background therapy
Participants: 241
Sites: 85
Countries: United States

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.